Tekla Life Sciences Investors (HQL) Insider Trading
- $7,085,451.16
- $3,628,684.07
- May 7, 2025
- Saba Capital Management, L.P.
Trader Name | Date | Title | Amount | Price | Type | Total Value |
---|---|---|---|---|---|---|
May 7, 2025 | Major Shareholder | 1,366 | $12.19 | Sell | $16,651.54 | |
April 17, 2025 | Major Shareholder | 9,144 | $11.78 | Sell | $107,716.32 | |
April 14, 2025 | Major Shareholder | 15,400 | $11.67 | Sell | $179,718.00 | |
April 10, 2025 | Major Shareholder | 30,156 | $11.14 | Sell | $335,937.84 | |
April 4, 2025 | Major Shareholder | 6,889 | $11.57 | Sell | $79,705.73 | |
April 2, 2025 | Major Shareholder | 29,102 | $12.28 | Sell | $357,372.56 | |
March 31, 2025 | Major Shareholder | 48,623 | $12.58 | Sell | $611,677.34 | |
March 27, 2025 | Major Shareholder | 32,922 | $13.01 | Sell | $428,315.22 | |
Feb. 26, 2025 | Major Shareholder | 200 | $13.62 | Sell | $2,724.00 | |
Feb. 12, 2025 | Major Shareholder | 36,536 | $13.75 | Sell | $502,370.00 | |
Feb. 10, 2025 | Major Shareholder | 42,987 | $13.95 | Sell | $599,668.65 | |
Feb. 3, 2025 | Major Shareholder | 1,846 | $14.03 | Sell | $25,899.38 | |
Jan. 31, 2025 | Major Shareholder | 15,143 | $14.27 | Sell | $216,090.61 | |
Jan. 29, 2025 | Major Shareholder | 11,674 | $14.12 | Sell | $164,836.88 | |
Aug. 23, 2024 | Director | 650 | $15.37 | Buy | $9,990.50 | |
July 16, 2024 | Director | 1,000 | $15.53 | Buy | $15,530.00 | |
June 26, 2024 | Major Shareholder | 100 | $14.07 | Buy | $1,407.00 | |
June 24, 2024 | Major Shareholder | 13,812 | $14.08 | Buy | $194,472.96 | |
June 12, 2024 | Major Shareholder | 2,400 | $13.88 | Buy | $33,312.00 | |
June 10, 2024 | Major Shareholder | 9,704 | $13.71 | Buy | $133,041.84 | |
June 6, 2024 | Major Shareholder | 9,598 | $13.80 | Buy | $132,452.40 | |
June 4, 2024 | Major Shareholder | 33,357 | $13.50 | Buy | $450,319.50 | |
May 30, 2024 | Major Shareholder | 669 | $13.05 | Buy | $8,730.45 | |
May 28, 2024 | Major Shareholder | 8,714 | $13.38 | Buy | $116,593.32 | |
May 23, 2024 | Major Shareholder | 1,303 | $13.50 | Buy | $17,590.50 | |
May 15, 2024 | Major Shareholder | 34,755 | $14.19 | Buy | $493,173.45 | |
May 10, 2024 | Major Shareholder | 57,862 | $13.86 | Buy | $801,967.32 | |
May 8, 2024 | Major Shareholder | 10,986 | $13.70 | Buy | $150,508.20 | |
May 6, 2024 | Major Shareholder | 10,713 | $13.62 | Buy | $145,911.06 | |
May 2, 2024 | Major Shareholder | 26,274 | $13.46 | Buy | $353,648.04 | |
April 30, 2024 | Major Shareholder | 16,573 | $13.13 | Buy | $217,603.49 | |
April 26, 2024 | Major Shareholder | 120,304 | $13.00 | Buy | $1,563,952.00 | |
April 24, 2024 | Major Shareholder | 20,529 | $13.12 | Buy | $269,340.48 | |
April 22, 2024 | Major Shareholder | 2,022 | $12.88 | Buy | $26,043.36 | |
April 18, 2024 | Major Shareholder | 81,738 | $12.80 | Buy | $1,046,246.40 | |
April 9, 2024 | Director | 400 | $13.32 | Buy | $5,328.00 | |
Jan. 2, 2024 | Director | 1,000 | $13.80 | Buy | $13,800.00 | |
Sept. 25, 2023 | President | 10,096 | $12.39 | Buy | $125,089.44 | |
Sept. 20, 2023 | President | 12,000 | $12.68 | Buy | $152,160.00 | |
March 23, 2022 | Director | 92 | $16.27 | Buy | $1,496.84 | |
Jan. 26, 2022 | Director | 593 | $17.54 | Buy | $10,401.22 | |
Aug. 11, 2021 | President | 6,403 | $21.63 | Buy | $138,496.89 | |
Oct. 26, 2020 | President | 6,175 | $17.52 | Buy | $108,186.00 | |
Oct. 21, 2020 | President | 5,950 | $17.75 | Buy | $105,612.50 | |
May 21, 2020 | President | 5,950 | $17.74 | Buy | $105,553.00 | |
March 17, 2020 | President | 8,300 | $13.27 | Buy | $110,141.00 | |
Jan. 25, 2018 | Director | 1,300 | $21.04 | Buy | $27,352.00 |
Insiders are both buying and selling Tekla Life Sciences Investors stock.
The insider traders at Tekla Life Sciences Investors are: Saba Capital Management, L.P., Daniel R Omstead, Kathleen Goetz, Thomas M Kent, Bill Maher, Todd Reit, Daniel R. Omstead, and Rose Dimartino
The most active insider trader at Tekla Life Sciences Investors is Saba Capital Management, L.P. with 33 trades.
Saba Capital Management, L.P. has sold the most Tekla Life Sciences Investors stock with a total value of $3,645,335.61.
Saba Capital Management, L.P. has bought the most Tekla Life Sciences Investors stock with a total value of $6,157,720.77.
The most recent insider trade for Tekla Life Sciences Investors was on May 7, 2025.
The single biggest insider buy for Tekla Life Sciences Investors was from Saba Capital Management, L.P. with a total value of $1,563,952.00 on April 26, 2024.
The single biggest insider sell for Tekla Life Sciences Investors was from Saba Capital Management, L.P. with a total value of $611,677.34 on March 31, 2025.